Overview
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Status:
Completed
Completed
Trial end date:
2017-12-12
2017-12-12
Target enrollment:
0
0
Participant gender:
All
All
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic DermatitisPhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Taro Pharmaceuticals USA
Criteria
Inclusion Criteria:- Parent/legal guardian has signed informed consent form, which meets all criteria of
current FDA regulations.
Exclusion Criteria:
- Females who are pregnant, nursing, planning to become pregnant during the duration of
the study, or if of child-bearing potential and sexually active and not prepared to
use appropriate contraceptive methods to avoid pregnancy